Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000032459
Abstract: Rationale: Malignant pleural mesothelioma (MPM) is a malevolent tumor originated from pleura and often leads to poor prognosis. Chemotherapy of pemetrexed and cisplatin combined with antiangiogenic therapy of bevacizumab is recommended as the first-line regimen… read more here.
Keywords: combined anlotinib; tislelizumab combined; line; line treatment ... See more keywords